While semaglutide remains on the shortage list, Novo Nordisk noted last week that the last remaining dose in short supply — the lowest dose of Wegovy — is now listed as available, CNN reported. “We’re ...

You might well think that it sounds too good to be true - a pill that means you can enjoy alcohol without suffering any ...

JPMorgan placed shares of Novo Nordisk (NVO) on “Positive Catalyst Watch” ahead ... with the potential for tolerability that is likely to be in the range of Wegovy and Zepbound’s approved labels, and ...

Novo Nordisk is working on a new obesity drug that could help patients ... Semaglutide, the GLP-1 drug that Novo sells under ...

You'll probably recognize their names after seeing them in the news or across social media: Ozempic and Wegovy (made by Novo ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

With the rise in the popularity of weight loss drugs like ‘Wegovy’ and ‘Ozempic,’ we’re learning a counterfeit market has ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Investing.com -- Novo Nordisk (CSE: NOVOb) has been placed on JPMorgan’s Catalyst Watch list, signaling heightened anticipation as the company approaches a pivotal moment in its development pipeline.

U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for diabetes and weight loss, according to a review of patient data published on Monday, the ...